Feeds:
Posts
Comments

Posts Tagged ‘low-risk patients’

NEW PROSTATE CANCER INFOLINK:  How often after prostate surgery should a “low risk” patient have his PSA tested to check if the cancer is coming back? READ MORE>

Tollefson et al. conclude that,  in low-risk patients, the risk of biochemical failure is inversely proportional to time for which the PSA is undetectable after radical prostatectomy.

They go on to suggest that taking PSA levels every two years should be sufficient to identify the majority of low-risk patients who experience biochemical progression.

The “New” Prostate Cancer InfoLink would certainly agree that annual PSA testing is probably unnecessary in the majority of patients who are treated surgically for low-risk disease if their PSA is undetectable after surgery.

However, the key question is how long should annual PSA testing be carried out before the patient can be switched to testing every two (or perhaps even every three) years.

Based on this paper, it would seem likely that even low-risk patients should all receive at least annual testing for three years after surgery.

Read Full Post »

URO TODAY: Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, but there is no significant benefit for low-risk patients. READ MORE>

Read Full Post »

JULY 3: NEW PROSTATE CANCER INFOLINK: Researchers have reported data showing that the historically conventional sextant (6-core) biopsy can not accurately diagnose prostate cancer in low-risk patients with unilateral, organ-confined (pT2a,b) disease. READ MORE>

Read Full Post »